Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06172478
What this trial is testing

HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMelanomaHead and Neck Cancer+11 more
Daiichi Sankyo 740
Testing effectiveness (Phase 2)Looking for participantsNCT06775678
What this trial is testing

Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer

Who this might be right for
Lung CancersRadiation Treatment for Tumors
Tianjin Medical University Cancer Institute and Hospital 84
Testing effectiveness (Phase 2)Looking for participantsNCT07098338
What this trial is testing

Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 278
Large-scale testing (Phase 3)Study completedNCT00520676
What this trial is testing

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 260
Testing effectiveness (Phase 2)UnknownNCT00278187
What this trial is testing

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Jonsson Comprehensive Cancer Center
Not applicableStudy completedNCT00922025
What this trial is testing

Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 186
Early research (Phase 1)Looking for participantsNCT04147078
What this trial is testing

Personalized DC Vaccine for Postoperative Cancer

Who this might be right for
Gastric CancerHepatocellular CarcinomaNon-Small-Cell Lung Cancer+1 more
Sichuan University 80
Testing effectiveness (Phase 2)Study completedNCT00985855
What this trial is testing

Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
Institut de Cancérologie de la Loire 91
Early research (Phase 1)Looking for participantsNCT06641609
What this trial is testing

A Phase I Study of CFT8919 in Patients With Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Betta Pharmaceuticals Co., Ltd. 166
Testing effectiveness (Phase 2)Study completedNCT00078455
What this trial is testing

Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small-Cell Lung Carcinoma
Genzyme, a Sanofi Company
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07551778
What this trial is testing

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Colorectal CancerAdvanced Solid Tumors+2 more
BOE Technology Group Co., Ltd. 42
Large-scale testing (Phase 3)Study completedNCT00532155
What this trial is testing

Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
CarcinomaNon Small Cell Lung
Sanofi 913
Not applicableEnded earlyNCT04878952
What this trial is testing

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Who this might be right for
Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIRecurrent Non Small Cell Lung Cancer
NRG Oncology 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04619004
What this trial is testing

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo 277
Testing effectiveness (Phase 2)Active Not RecruitingNCT06114511
What this trial is testing

BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 78
Large-scale testing (Phase 3)UnknownNCT03866499
What this trial is testing

BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Who this might be right for
NSCLC
Beta Pharma Shanghai 369
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Looking for participantsNCT06865339
What this trial is testing

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Who this might be right for
NSCLCLocally Advanced
Montefiore Medical Center 76
Testing effectiveness (Phase 2)Looking for participantsNCT07680764
What this trial is testing

Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 160
Testing effectiveness (Phase 2)Study completedNCT03744468
What this trial is testing

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inHNSCC for Phase 2 Dose ExpansionNSCLC for Phase 2 Dose Expansion
BeiGene 147
Next Page